PUBLIC CONTRACT · 2019
41034119 - Aq urgente medicamentos
- Contract value
- €55,164.14
- Signed on
- 5 November 2019
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 6008731PUBLISHED SUBJECT
Atezolizumab 60 mg/ml Sol inj Fr 20 ml IV BEVACIZUMAB,25 MG / ML SOL INJ FR 16 ML IV Daratumumab 20 mg/ml Sol inj Fr 20 ml IV
Parties involved
- Place of performance
- Portugal, Setúbal, Setúbal
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- JANSSEN - CILAG FARMACÊUTICA, LDA · Tax ID 500189412
- Awardee
- Roche Farmacêutica Química, Lda. · Tax ID 500233810
Values and timeline
- Contract price
- €55,164.14
- Procedure base price
- €55,164.14
- Total effective price
- Not reported on Portal BASE
- Publication date
- 7 November 2019
- Award date
- 5 November 2019
- Signing date
- 5 November 2019
- Performance period
- 10 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Preço ou custo
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea iii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL 111-B/2017 ) e DLR no 34/2008/M, de 14.08 (DLR n.º 6/2018/M)
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 4252311
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.